News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Suven Life Sciences Ltd Bags Pharmexcil's "Platinum Patent Award"

10/4/2012 10:18:13 AM

HYDERABAD, INDIA (Oct 4, 2012) – Suven Life Sciences Ltd (SUVEN) announces today that they bagged Pharmexcil’s “Platinum Patent Award” for securing the most number of product and process patents under overall category fourth year in a row. The Awards were presented during the "Awards Function for Exports and patents during India-Asia-Pacific International Pharma Business Meet” organized by Pharmexcil, Department of Commerce and Department of Pharmaceuticals, Government of India.

Suven secured 96 product patents for their NCE’s and 9 process patents during 2011-2012 from several countries including all the developed countries like USA, Europe, Japan, Australia and Canada etc. So far Suven secured a total of 541 product patents globally for their NCE’s and 36 process patents. Suven initiated drug discovery research in 2002 and focused on central nervous system (CNS) disorders to discover and develop innovative, cost-effective medicines that address significant unmet medical needs in the treatment of cognitive impairment associated with neurodegenerative disorders such as Alzheimer’s disease, Attention deficient hyperactivity disorder (ADHD), Huntington’s disease, Parkinson, Schizophrenia and also in the area of depression, Pain and Obesity.

"We are very pleased by the grant of these patents to Suven globally for our pipeline of molecules in CNS arena that are being developed for the treatment of various unmet medical needs which has an estimated $50 billion market potential globally" says Venkat Jasti, CEO of Suven.

Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class therapies through the use of GPCR targets. The Company has twelve (12) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and obesity in addition to developmental candidate SUVN-502 for Alzheimer's disease and Schizophrenia.

For more information please visit our Web site at

Safe Harbor Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.

Read at

comments powered by Disqus